To the general secretary, NUF

Att. John Frideriksson

**Annual report from NoRenCa 2022/2023**

*The NORENCA group is a collaboration group, and was established in Malmö in 2015. The focus has been on*

*establishing a well-functioning scientific collaboration and working among the Scandinavian countries.*

***Members:***

**Representation:**

**Sweden**: Pernilla Sundquist, Börje Ljungberg

**Finland**: Harri Nisen, Petrus Järvinen

**Denmark**: Lars Lund (Chair), Nessn Azawi

**Norway:** Frode Nilsen, Christian Beisland

**Iceland**: Eirikur Gudmundsson

Two member from the group will stop this year: Eirikur Gudmundsson. and Harry Nissen. The group wants to thank the two former members for their hard work in the group and also positive attitude to discussion concerning research areas. The group will really miss them.

The new Finnish  member of Norenca will be Thea Veitonmäki, a urologist from University Hosp. Of Tampere. She will start in Norenca  from NUF 2024 meeting

The group has asked Eirikur G, Iceland to talk with the national societies in order to appoint the new member for the NoRenCa group.

***Meetings:***

There have been three online meetings during the past year and one 2-days seminar in Stockholm. During this seminar the group planned the two hours session at the NUF meeting in Bergen and also discussed several projects which was going to be initiated this year.

The group will held an en-face meeting at the NUF meeting in Bergen 6th of June.

***Scientific work:***

The group has individually and nationally participated in several publications concerning different aspects of renal cancer. Some members of the group has also presented their work on national and international conferences such as EAU, AUA and IEKCS. Some of the members of NorenCa are involved in the IEKCS steering committee has participated as chairman and presented lectures, oral presentations for accepted abstracts and posters. One member is chairman of the RCC guidelines in the EAU.

**On going studies:**

* The NORDIC-SUN-Trial. Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a DaRenCa and NoRenCa Trial Evaluating the Impact of Surgery or No Surgery. Principal investigator: Niels Fristrup, Aarhus Denmark.

**Studies in pipeline:**

* Prospective Multicenter Study Comparing Surgery vs Active Surveillance In Patients With Bosniak 3 Renal Cyst. Principal investigator : Harry Nisen.
* A prospective Nordic Database that includes patients with renal cancer regarding active surveillance strategy as well as aggressive renal cancer. Nessn and Petrus will work on the Nordic protocol and present it to the NoRenCa group.

For summary of the meetings please visit NUF´s website.

Lars Lund

Chairman of NoRenCa